

VYKAT XR- diazoxide choline tablet, film coated

Soleno Therapeutics, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use VYKAT XR safely and effectively. See full prescribing information for VYKAT XR.

VYKAT™ XR (diazoxide choline) extended-release tablets, for oral use
Initial U.S. Approval: 1973

INDICATIONS AND USAGE

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). (1)

DOSAGE AND ADMINISTRATION

- Prior to initiation, test fasting plasma glucose and HbA1c; optimize blood glucose in patients who have hyperglycemia. (2.1)
- Do not substitute with diazoxide oral suspension. (2.1)
- Administer orally once daily. (2.2)
- Recommended starting dosage and titration schedule is based on patient's body weight. (2.2)

Weight	Starting Dosage	Titration Dosage	Titration Dosage	Target Maintenance Dose
	Weeks 1 and 2	Weeks 3 and 4	Weeks 5 and 6	
20 to <30 kg	25 mg	50 mg	75 mg	100 mg
30 to <40 kg	75 mg	150 mg	150 mg	150 mg
40 to <65 kg	75 mg	150 mg	225 mg	225 mg
65 to <100 kg	150 mg	225 mg	300 mg	375 mg
100 to <135 kg	150 mg	300 mg	375 mg	450 mg
≥135 kg	150 mg	300 mg	450 mg	525 mg

- The maximum recommended dosage is 5.8 mg/kg/day or 525 mg per day. (2.2)
- Interrupt VYKAT XR or reduce dosage for clinically significant elevations in fasting glucose or HbA1c; consider dosage reduction or interruption for clinically significant fluid overload. (2.3)
- See full prescribing information for VYKAT XR dosage modifications due to drug interactions (2.4)
- Following dosage interruption or a missed dose of 7 days or more, re-titrate according to Table 1 or Table 2. (2.5)

DOSAGE FORMS AND STRENGTHS

- Extended-release tablets: 25 mg, 75 mg, and 150 mg of diazoxide choline. (3)

CONTRAINDICATIONS

- Known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides. (4)

WARNINGS AND PRECAUTIONS

- *Hyperglycemia*: Hyperglycemia, including diabetic ketoacidosis, has been reported. During treatment, monitor fasting glucose and HbA1c. Monitor fasting glucose more frequently during first few weeks of treatment in patients with risk factors for hyperglycemia. (2.3, 5.1)
- *Risk of Fluid Overload*: Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. (2.3, 5.2)

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥10% and at least 2% greater than in placebo) are hypertrichosis, edema, hyperglycemia, and rash. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Soleno Therapeutics, Inc. at 1-833-765-3661 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----**DRUG INTERACTIONS**-----

- *Strong CYP1A2 Inhibitors:* Reduce VYKAT XR dosage. (2.4, 7)
- *CYP1A2 Substrates:* Concomitant use with VYKAT XR is not recommended. (7)
- See full prescribing information for additional clinically significant drug interactions. (7)

-----**USE IN SPECIFIC POPULATIONS**-----

- *Renal Impairment or Hepatic Impairment:* Use is not recommended. (8.6, 8.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 3/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Recommendations Prior to VYKAT XR Initiation
- 2.2 Dosage and Administration Recommendations
- 2.3 Monitoring and Dosage Modifications Due to Adverse Reactions
- 2.4 Dosage Modifications for Concomitant Use with Strong CYP1A2 Inhibitors
- 2.5 Recommendations Regarding Dosage Interruption, Missed Dose, or Discontinuation of Treatment

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Hyperglycemia
- 5.2 Risk of Fluid Overload

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).

2 DOSAGE AND ADMINISTRATION

2.1 Important Recommendations Prior to VYKAT XR Initiation

Laboratory Testing Prior to VYKAT XR Initiation

Prior to initiating treatment with VYKAT XR, test fasting plasma glucose (FPG) and HbA1c and optimize blood glucose in patients who have hyperglycemia [see Warnings and Precautions (5.1)].

For fasting glucose and HbA1c monitoring recommendations during VYKAT XR treatment and for dosage modifications based on results, see Dosage and Administration (2.3).

Important Information Regarding Substitution

Do not substitute VYKAT XR with diazoxide oral suspension because the pharmacokinetic profiles are different [see Clinical Pharmacology (12.3)].

2.2 Dosage and Administration Recommendations

Administer VYKAT XR orally with or without food once daily [see Clinical Pharmacology (12.3)].

Swallow tablets whole. Do not split, crush, or chew the extended-release tablets because doing so may compromise the extended-release characteristics, efficacy, or safety of VYKAT XR.

The recommended oral dosage of VYKAT XR is based on body weight. The recommended starting dosage and titration schedule of VYKAT XR are shown in Table 1.

Table 1: Recommended Starting Dosage and Titration Regimen in Adults and Pediatric Patients 4 Years of Age and Older

Weight	Recommended Once Daily Dosage			
	Starting Dosage	Titration Dosage	Titration Dosage	Target Maintenance Dose
	Weeks 1 and 2	Weeks 3 and 4	Weeks 5 and 6	
20 kg to <30 kg	25 mg	50 mg	75 mg	100 mg
30 kg to <40 kg				

30 kg to <40 kg	75 mg	150 mg	150 mg	150 mg
40 kg to <65 kg	75 mg	150 mg	225 mg	225 mg
65 kg to <100 kg	150 mg	225 mg	300 mg	375 mg
100 kg to <135 kg	150 mg	300 mg	375 mg	450 mg
≥135 kg	150 mg	300 mg	450 mg	525 mg

The maximum recommended dosage of VYKAT XR is 5.8 mg/kg/day or 525 mg per day. Dosages above 5.8 mg/kg/day or 525 mg per day have not been evaluated in patients with PWS.

2.3 Monitoring and Dosage Modifications Due to Adverse Reactions

Elevations in Fasting Glucose or HbA1c

After initiating treatment with VYKAT XR, monitor:

- Fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated.
- HbA1c every 3 months and as clinically indicated.

Monitor fasting glucose more frequently during the first few weeks of VYKAT XR treatment in patients with risk factors for hyperglycemia.

If clinically significant elevations in fasting glucose or HbA1c occur during treatment, temporarily interrupt VYKAT XR or reduce the dosage until glycemic parameters are appropriately managed. Consider initiation or adjustment of standard antidiabetic therapy(ies). If clinically significant glucose elevations are noted during titration, titrate over a longer duration and/or to a lower dosage [*see Warnings and Precautions (5.1)*].

Fluid Overload

Monitor for signs or symptoms of edema or fluid overload. Consider dosage reduction or temporary dosage interruption in the event of clinically significant fluid overload. If clinically significant fluid overload is noted during titration, titrate over a longer duration and/or to a lower dosage [*see Warnings and Precautions (5.2)*].

Titration After Resolution of Fluid Overload or Elevation in Fasting Glucose or HbA1c

If fluid overload or elevations in fasting glucose or HbA1c resolve after a dosage reduction:

- For patients weighing less than 30 kg, titrate the dosage in increments of no more than 25 mg every 2 weeks or titrate over longer duration to a maximum dosage of 5.8 mg/kg/day.
- For patients weighing greater than or equal to 30 kg, titrate the dosage in increments of no more than 75 mg every 2 weeks or titrate over longer duration to a maximum dosage of 5.8 mg/kg/day.

For recommendations on resuming VYKAT XR after dosage interruption, see *Dosage and Administration (2.5)*.

2.4 Dosage Modifications for Concomitant Use with Strong CYP1A2 Inhibitors

VYKAT XR dosage modifications for concomitant use with strong CYP1A2 inhibitors are shown in Table 2[see *Drug Interactions (7)*].

Table 2: VYKAT XR Dosage Modifications for Concomitant Use with Strong CYP1A2 Inhibitors

Weight	VYKAT XR Recommended Once Daily Dosage			
	Starting Dosage	Titration Dosage	Titration Dosage	Target Maintenance Dose
	Weeks 1 and 2	Weeks 3 and 4	Weeks 5 and 6	
20 to <30 kg	25 mg	25 mg	50 mg	75 mg
30 to <40 kg	50 mg	100 mg	100 mg	100 mg
40 to <65 kg	50 mg	100 mg	150 mg	150 mg
65 to <100 kg	100 mg	150 mg	200 mg	250 mg
100 to <135 kg	100 mg	200 mg	250 mg	300 mg
≥135 kg	100 mg	200 mg	300 mg	325 mg

Based on clinical response, VYKAT XR may be titrated to a maximum recommended dosage of 3.6 mg/kg/day. The VYKAT XR daily dosage should not exceed 325 mg per day.

No dosage modification is recommended when VYKAT XR is concomitantly used with moderate CYP1A2 inhibitors.

2.5 Recommendations Regarding Dosage Interruption, Missed Dose, or Discontinuation of Treatment

Following a dosage interruption or missed dose of:

- Less than 7 days, resume VYKAT XR at the previous dosage
- 7 days or more, re-titrate VYKAT XR according to Table 1 or 2, as appropriate [see *Dosage and Administration (2.2, 2.4)*]

Treatment with VYKAT XR can be discontinued without tapering.

3 DOSAGE FORMS AND STRENGTHS

Extended-release tablets:

- VYKAT XR 25mg of diazoxide choline: white, capsule-shaped, film-coated, waxed tablets, debossed with S-25 on one side.
- VYKAT XR 75 mg of diazoxide choline: white, round, standard convex-shaped, film-coated, waxed tablets, debossed with S-75 on one side.
- VYKAT XR 150 mg of diazoxide choline: white, oval-shaped, film-coated, waxed tablets, debossed with S-150 on one side.

4 CONTRAINDICATIONS

VYKAT XR is contraindicated in patients with known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides. Erythema multiforme has been reported with VYKAT XR [see *Adverse Reactions* (6)].

5 WARNINGS AND PRECAUTIONS

5.1 Hyperglycemia

VYKAT XR increases blood glucose, due primarily to an inhibition of insulin release from the pancreas. Hyperglycemia, including severe adverse reactions associated with diabetic ketoacidosis, occurred in VYKAT XR-treated patients during clinical trials [see *Adverse Reactions* (6)].

Precipitating conditions for diabetic ketoacidosis may include reduction in the dosages of concomitant antihyperglycemic medications, increase in the dosages of concomitant growth hormone, intercurrent illness, surgery, volume depletion or alcohol abuse. Signs and symptoms of ketoacidosis include nausea, vomiting, abdominal pain, generalized malaise and shortness of breath.

Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. After initiating treatment with VYKAT XR, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c [see *Dosage and Administration* (2.3)]. Monitor fasting glucose more frequently for the first few weeks of treatment with VYKAT XR in patients with risk factors for hyperglycemia, such as obesity, elevated FPG, HbA1c at the upper limit of normal or above, concomitant use of growth hormone, or concomitant use of systemic corticosteroids.

Advise patients of the signs and symptoms of hyperglycemia (e.g., excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss). If a patient experiences hyperglycemia after initiating treatment with VYKAT XR, monitor fasting glucose as clinically indicated, and at least twice weekly until fasting glucose decreases to normal levels. Consider monitoring ketones in patients with worsening hyperglycemia.

If hyperglycemia is treated with anti-hyperglycemic medication during VYKAT XR treatment, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks and as clinically indicated. Consider consultation with a healthcare provider with expertise in the treatment of hyperglycemia and counsel patients on lifestyle changes. Based on the severity of the hyperglycemia, VYKAT XR may require dosage interruption, reduction, or discontinuation in order to avoid progression to ketoacidosis [see *Dosage and Administration* (2.3)].

5.2 Risk of Fluid Overload

Edema, including general, localized, and peripheral edema, occurred in 27% of VYKAT XR-treated patients versus 12% of placebo-treated patients in the placebo-controlled trial with treatment-naïve subjects (Study 1). Severe adverse reactions associated with fluid overload, including pulmonary edema, were reported in VYKAT XR-treated patients during clinical trials [see *Adverse Reactions* (6)].

The antidiuretic property of diazoxide may lead to significant fluid retention, which may precipitate congestive heart failure in patients with compromised cardiac reserve. VYKAT

XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.

Monitor for signs or symptoms of edema or fluid overload and consider appropriate clinical management, which may include VYKAT XR dosage reduction or treatment interruption, if clinically significant [see Dosage and Administration (2.3)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

- Hyperglycemia [see Warnings and Precautions (5.1)]
- Risk of Fluid Overload [see Warnings and Precautions (5.2)]

Adverse Reactions from Clinical Studies of VYKAT XR in Patients with PWS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the clinical study development program for treatment of hyperphagia in patients aged 4 years and older with PWS, a total of 125 patients received at least 1 dose of VYKAT XR. Patients received dosages of VYKAT XR up to 5.8 mg/kg/day (up to a maximum dosage of 525 mg/day) for up to 4.86 years (median: 3.0 years) in the following studies:

- Study 1: 13-week, randomized, double-blind, placebo-controlled, parallel-arm study in which 126 patients were randomized in a 2:1 ratio to VYKAT XR or placebo and received at least one dose of VYKAT XR.
- Study 2-OLE: A long-term, open-label, maintenance treatment period in 115 patients (mean duration 2.6 years; maximum duration 4.3 years) who had previously been enrolled in Study 1.
- Study 2-RWP: A 16-week, double-blind, placebo-controlled, randomized withdrawal treatment period, in which 77 patients who had completed Study 1 and Study 2-OLE were randomized in a 1:1 ratio to VYKAT XR or placebo [see Clinical Studies (14)].
- Study 3: A long-term, open-label, maintenance study in 77 patients who had completed Study 1 and Study 2-OLE.

Adverse reactions leading to discontinuation in VYKAT XR-treated patients included aggression, diabetes mellitus, fluid retention, hirsutism, hyperglycemia, lower respiratory tract infection, peripheral edema, pulmonary edema, and papular rash.

The primary safety analyses are based on Study 1. The most common adverse reactions (10% or more and at least 2% greater than in placebo) in Study 1 were hypertrichosis, edema, hyperglycemia, and rash.

Table 3 presents adverse reactions that occurred in at least 5% of patients in Study 1 receiving VYKAT XR and 2% more frequently in VYKAT XR-treated patients than placebo.

Table 3: Adverse Reactions Occurring in ≥5% of Patients with PWS Receiving VYKAT XR and at Least 2% Greater than Placebo in Study 1

	VYKAT XR	Placebo
--	----------	---------

Adverse Reaction	(N=84)	(N=42)
Hypertrichosis	36%	14%
Edema*	27%	12%
Hyperglycemia†	17%	5%
Rash‡	12%	2%
Pyrexia	6%	0%
Arthralgia	5%	2%
Influenza	5%	2%
Nasopharyngitis	5%	2%

* Edema includes peripheral edema, periorbital edema, swelling face, pulmonary edema, and peripheral swelling.

† Hyperglycemia includes type 2 diabetes mellitus.

‡ Rash includes contact dermatitis, erythema multiforme, maculo-papular rash, papular rash, and urticaria.

In Study 2-RWP, the adverse reactions that occurred most frequently (at least 5%) and to a greater extent than placebo included:

Immune System Disorders: Seasonal allergy

Investigations: Increased weight

Nervous System Disorders: Hyperphagia, anxiety, affect lability, anger, compulsive hoarding, suicidal ideation

Respiratory Disorders: Streptococcal pharyngitis, upper respiratory infection

Skin and Subcutaneous Tissue Disorders: Hirsutism

Erythema multiforme was reported in one subject in Study 1. One subject in Study 3 experienced a serious adverse reaction of diabetic ketoacidosis.

Adverse Reactions from Clinical Trials or Postmarketing Experience of Diazoxide in An Unapproved Population

The following adverse reactions associated with use of diazoxide for an unapproved population have been identified in clinical studies or post-marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Hypersensitivity

Investigations: Increased serum uric acid, transient neutropenia, thrombocytopenia, decreased hemoglobin/hematocrit, eosinophilia

Respiratory Disorders: Pulmonary hypertension

Special Senses: Cataracts

Musculoskeletal and Connective Tissue Disorders: Abnormal facial features

7 DRUG INTERACTIONS

Table 4 displays clinically significant drug interactions with VYKAT XR.

Table 4: Clinically Significant Drug Interactions with VYKAT XR

Strong CYP1A2 Inhibitors*	
<i>Prevention or Management</i>	Reduce the dosage of VYKAT XR when concomitantly used with strong inhibitors of CYP1A2 [see <i>Dosage and Administration</i> (2.4)].
<i>Mechanism and Clinical Effect(s)</i>	VYKAT XR is a CYP1A2 substrate. Concomitant use of VYKAT XR with strong CYP1A2 inhibitors increases exposure of diazoxide, which may increase the frequency and/or severity of adverse reactions from VYKAT XR [see <i>Clinical Pharmacology</i> (12.3)].
CYP1A2 Substrates*	
<i>Prevention or Management</i>	Concomitant use of VYKAT XR with CYP1A2 substrates is not recommended.
<i>Mechanism and Clinical Effect(s)</i>	VYKAT XR is an inhibitor of CYP1A2. Concomitant use of VYKAT XR with CYP1A2 substrates increases exposure of these substrates. This may increase the frequency and/or severity of adverse reactions from such substrates.
Strong CYP3A4 Inhibitors*	
<i>Prevention or Management</i>	Monitor the frequency and severity of adverse reactions from VYKAT XR. A dosage reduction of VYKAT XR may be needed when used concomitantly with strong CYP3A4 inhibitors.
<i>Mechanism and Clinical Effect(s)</i>	Concomitant use of VYKAT XR with strong CYP3A4 inhibitors increases exposure of diazoxide, which may increase the frequency and/or severity of adverse reactions from VYKAT XR [see <i>Clinical Pharmacology</i> (12.3)].
Dual Strong CYP3A4 / Moderate 1A2 Inducers*	
<i>Prevention or Management</i>	Concomitant use of VYKAT XR with dual strong CYP3A4/moderate CYP1A2 inducers is not recommended.
<i>Mechanism and Clinical Effect(s)</i>	VYKAT XR is a substrate of CYP3A4 and CYP1A2. Concomitant use of VYKAT XR with strong CYP3A4/moderate 1A2 inducers may decrease exposure of VYKAT XR. This may decrease the efficacy of VYKAT XR [see <i>Clinical Pharmacology</i> (12.3)].
Drugs Highly Bound to Protein	
<i>Prevention or Management</i>	Monitor international normalized ratio (INR) in patients who use coumarin or its derivatives concomitantly with VYKAT XR. Dosage modification of coumarin or its derivatives may be needed when used concomitantly with VYKAT XR.

<i>Management</i>	Monitor diphenylhydantoin serum levels when VYKAT XR is used concomitantly with diphenylhydantoin. Dosage modification of diphenylhydantoin may be needed when used concomitantly with VYKAT XR.
<i>Mechanism and Clinical Effect(s)</i>	<p>Diazoxide is highly bound to serum proteins.</p> <p>Diazoxide may displace other drugs which are also highly bound to protein resulting in higher or lower blood levels of the concomitantly used drugs. The impact of protein binding displacement is expected to be clinically important for drugs with narrow therapeutic range such as coumarin or its derivatives and diphenylhydantoin. Protein binding displacement may result in an increased risk of adverse reactions due to higher blood levels of coumarin or its derivative or loss of efficacy due to lower exposures of diphenylhydantoin.</p>
Thiazide or Other Diuretics	
<i>Prevention or Management</i>	Monitor for signs and symptoms of hyperglycemia [see <i>Warnings and Precautions (5.1)</i>] and hyperuricemia when VYKAT XR is used concomitantly with thiazides or other diuretics. Dosage adjustment of VYKAT XR or diuretics may be needed when VYKAT XR is concomitantly used with diuretics.
<i>Mechanism and Clinical Effect(s)</i>	Both diazoxide and thiazides or other diuretics may produce hyperglycemia and hyperuricemia. The concomitant use of VYKAT XR with thiazides or other diuretics may potentiate the hyperglycemic and hyperuricemic effects of diazoxide [see <i>Adverse Reactions (6) and Clinical Pharmacology (12.2)</i>].

* See www.fda.gov/CYPandTransporterInteractingDrugs for examples of strong CYP1A2 and CYP3A4 inhibitors, sensitive CYP1A2 substrates, and dual strong CYP3A4 / moderate 1A2 inducers.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from case reports with diazoxide use during pregnancy are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or other adverse maternal outcomes.

Adverse reactions, including hyperglycemia, alopecia, and hypertrichosis lanuginosa, have been reported in neonates exposed to diazoxide in utero prior to delivery (see

Clinical Considerations).

In animal reproduction studies, oral gavage administration of diazoxide choline to pregnant rats during organogenesis at dose exposures equal to the human exposure of 525 mg resulted in no malformations. Maternal and fetal toxicities were observed at a dose approximately equal to the maximum recommended human dose (MRHD) of 525 mg based on AUC (*see Data*).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Diazoxide crosses the placenta and has been detected in cord blood. Based on adverse reactions reported in adults, in utero exposure of the infant prior to delivery may produce fetal or neonatal hyperbilirubinemia, thrombocytopenia, altered carbohydrate metabolism, and possibly other adverse reactions. Monitor infants who were exposed to diazoxide in utero for adverse reactions and treat accordingly.

Alopecia and hypertrichosis lanuginosa have occurred in a small number of infants whose mothers received oral diazoxide during the last 19 to 60 days of pregnancy. Abnormal hair growth was first noted at the age of one week and persisted when the infants were last seen at the ages of 5 months to one year. An infant born to a mother who was treated with oral diazoxide, 150 mg daily for 47 days prior to delivery, developed hyperglycemia which resolved after a 6-hour insulin infusion. Because there was an inappropriately low plasma insulin concentration for the degree of hyperglycemia, it was considered compatible with transplacental transfer of diazoxide causing inhibition of release of insulin from the neonatal pancreas.

Labor or Delivery

Intravenous administration of diazoxide during labor may cause cessation of uterine contractions, which may require administration of oxytocic agents to reinstate labor. However, this has not been reported with diazoxide when administered orally. Use caution in administering VYKAT XR during labor.

Data

Animal Data

Diazoxide choline was administered orally to pregnant rats during the period of organogenesis at doses of 40, 100, and 160 mg/kg/day (0.3, 0.6, and 1.2 times the MRHD of 525 mg based on AUC). No malformations were observed; however, decreased fetal body weights, delayed skeletal ossification, and increased fetal resorptions were observed at 160 mg/kg/day (a dose approximately equal to the MRHD based on AUC) which was a maternally toxic dose.

In a study in which rabbits were administered diazoxide intravenously, evidence of skeletal and cardiac teratogenic effects was noted at unknown multiples of the MRHD for diazoxide choline.

8.2 Lactation

Risk Summary

Diazoxide is present in human milk. There are no data on the effects of diazoxide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYKAT XR and any potential adverse effects on the breastfed child from VYKAT XR or from the underlying maternal condition.

Clinical Considerations

Because of potential adverse reactions, including hyperglycemia, monitoring the infant's blood glucose may be advisable, especially during the neonatal period.

8.4 Pediatric Use

The safety and effectiveness of VYKAT XR have been established for the treatment of hyperphagia in pediatric patients 4 years of age and older with PWS. Use of VYKAT XR for this indication is supported by efficacy data from an adequate and well-controlled study that included pediatric patients with PWS [see *Clinical Studies (14)*] and safety data from additional studies that included pediatric patients with PWS [see *Adverse Reactions (6)*], and the information on this use is described throughout the labeling.

The safety and effectiveness of VYKAT XR have not been established for the treatment of hyperphagia in pediatric patients with PWS less than 4 years of age.

Adverse Reactions in Pediatric Patients in an Unapproved Population

The following postmarketing adverse reactions have been reported with the use of other diazoxide products for the treatment of hyperinsulinemic hypoglycemia, an unapproved population [see *Adverse Reactions (6)*]:

- Pulmonary hypertension in pediatric patients less than 6 months of age, including neonates.
- Transient cataracts in association with hyperosmolar coma in a pediatric patient that subsided with correction of the hyperosmolarity.
- Development of abnormal facial features with chronic use in pediatric patients.

VYKAT XR is not approved and is not recommended for the treatment of hyperinsulinemic hypoglycemia.

Juvenile Animal Toxicity Data

Diazoxide choline was orally administered at doses of 29, 58, and 145 mg/kg/day to juvenile rats from weaning (postnatal day 21) through adulthood (postnatal day 91). Reduced body weight and body weight gains, correlated with decreased food consumption, occurred at doses \geq 58 mg/kg/day. Delayed sexual maturation occurred in males at \geq 58 mg/kg/day and in females at all doses. Decreased motor activity was observed in males at \geq 58 mg/kg/day, but no effect was observed on learning and memory at any dose in both males and females. The no adverse effect level (NOAEL) was 29 mg/kg/day, which results in exposures less than the clinical exposure at the maximum recommended human dose (MRHD) of 525 mg based on AUC.

8.5 Geriatric Use

Clinical studies of VYKAT XR did not include any subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

8.6 Renal Impairment

VYKAT XR has not been studied in patients with renal impairment. VYKAT XR is not recommended in patients with renal impairment.

8.7 Hepatic Impairment

VYKAT XR has not been studied in patients with hepatic impairment. VYKAT XR is not recommended in patients with hepatic impairment.

10 OVERDOSAGE


An overdose of VYKAT XR may cause marked hyperglycemia, which may be associated with ketoacidosis [see *Warnings and Precautions (5.1)*].

No specific antidotes for VYKAT XR are known. Monitor ketones in patients with severe hyperglycemia following overdose and consider insulin treatment if necessary. Treat severe hyperglycemia associated with ketoacidosis with prompt insulin administration and restoration of fluid and electrolyte balance. Because of VYKAT XR's long half-life (approximately 106 hours) in patients with PWS, the symptoms of overdose (hyperglycemia, with or without ketoacidosis) require prolonged surveillance for periods up to three weeks or until blood sugar levels stabilize within the patient's normal range. Consider contacting a Poison Help line (1-800-222-1222) or a medical toxicologist for overdose management recommendations for VYKAT XR.

11 DESCRIPTION

VYKAT XR contains diazoxide choline. Diazoxide choline is very slightly soluble to soluble in solvents dichloromethane, tetrahydrofuran, acetonitrile, and methanol and practically insoluble in solvents methyl *tert*-butyl ether. The pKa is 8.44 ± 0.01

Diazoxide choline is 7-Chloro-3-methyl-1 λ 6, 2,4-benzothiadiazin-2-ide 1,1-dioxide 2-hydroxyethyl(trimethyl)azanum. The empirical formula is $C_8H_6ClN_2O_2S \cdot C_5H_{14}NO$ and the molecular weight is 333.83 g/mole. The structural formula is:



VYKAT XR is for oral administration and is available as extended-release tablets in the following strengths: 25 mg tablet contains diazoxide choline 25 mg, equivalent to 17.2 mg diazoxide; 75 mg tablet contains diazoxide choline 75 mg, equivalent to 51.6 mg diazoxide; and 150 mg tablet contains diazoxide choline 150 mg, equivalent to 103.2 mg diazoxide.

Each tablet contains the following inactive ingredients: carnauba wax, colloidal silicon dioxide, dibasic calcium phosphate dihydrate, hypromellose, magnesium stearate, polyethylene oxide, silicified microcrystalline cellulose, talc, titanium dioxide, and triacetin.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The exact mechanism of action of diazoxide choline in the treatment of hyperphagia in patients 4 years of age and older with Prader-Willi syndrome (PWS) is unknown.

12.2 Pharmacodynamics

VYKAT XR resulted in a reduction in fasting plasma insulin from baseline through 1 year of treatment.

Diazoxide increases blood glucose, due primarily to an inhibition of insulin release from the pancreas.

Other pharmacodynamic effects of VYKAT XR include increased uric acid, renin secretion and IgG concentrations, and decreased cortisol secretion.

12.3 Pharmacokinetics

Absorption

Following oral administration, diazoxide choline is hydrolyzed to diazoxide prior to absorption. Peak diazoxide concentrations occur after 16 hours. VYKAT XR is expected to reach steady state after 7 days.

Effect of Food

Following administration of 150 mg diazoxide choline to healthy subjects, the C_{max} increased by 39% and AUC_{inf} was unchanged with a high-fat meal, compared to fasted conditions. The median T_{max} was 12 hours in the fasted state, and 8 hours in the fed state.

Distribution

The volume of distribution of diazoxide following oral administration is about 44.9 L. Diazoxide is extensively bound (91% to 93%) to plasma proteins (primarily human albumin), and crosses the blood-brain barrier.

Elimination

Metabolism

Diazoxide is mainly metabolized by CYP1A2 and to a minor extent by CYP3A4. Diazoxide is metabolized by oxidation or sulfate conjugation at the methyl group resulting in two inactive metabolites. Following long term administration in patients with PWS, only metabolite M1(3-hydroxymethyl-7-chloro-1,2,4- benzothiadiazine-1,1-dioxide) is detectable in circulation.

Excretion

Diazoxide is excreted almost exclusively in urine as free or conjugated compound. In

humans, following administration of radiolabeled diazoxide, 85 to 92% of the total dose was recovered in urine, with about 31% eliminated as unchanged drug. About 2% of the dose is eliminated in the feces. The terminal half-life following single-dose administration in healthy subjects was 28.7 to 32.4 hours. In patients with PWS, the estimated terminal half-life is 106 hours.

Specific Populations

Pediatric Patients

Approximately 72% of the patients with PWS were under 17 years of age at enrollment. There were no clinically relevant differences in pharmacokinetics in these participants compared to those observed in adult participants.

Male and Female Patients

No sex-related differences in pharmacokinetics have been observed in clinical trials of VYKAT XR in patients with PWS who have hyperphagia.

Patients with Renal or Hepatic Impairment

VYKAT XR has not been studied in patients with renal or hepatic impairment [see *Use in Specific Populations (8.6, 8.7)*].

Drug Interaction Studies

Drugs That Inhibit CYP1A2

VYKAT XR is metabolized by CYP1A2 and coadministration with a strong CYP1A2 inhibitor may increase exposure of diazoxide and decrease concentrations of diazoxide metabolites. In a clinical study with fluvoxamine (a strong CYP1A2 inhibitor), coadministration with fluvoxamine at an inhibitory dose increased single dose diazoxide C_{max} by 17.5% and AUC_{0-inf} by 60% compared to the same parameter measured on single dose in the absence of fluvoxamine co-administration [see *Drug Interactions (7)*].

Strong CYP3A4 Inhibitor

Physiology-based pharmacokinetic model-based analysis suggests that concomitant use of VYKAT XR with itraconazole (a strong CYP3A4 inhibitor) may increase the AUC_{inf} of VYKAT XR by 1.1 to 2-fold, compared to VYKAT XR alone. Itraconazole did not appreciably affect the C_{max} of VYKAT XR [see *Drug Interactions (7)*].

Strong CYP3A4 Inducers

Physiology-based pharmacokinetic model-based analysis suggests that concomitant use of VYKAT XR with rifampin (a strong CYP3A4 inducer and moderate CYP1A2 inducer) may decrease the C_{max} and AUC_{inf} of VYKAT XR by 14% to 30% and 40% to 70%, respectively, compared to VYKAT XR alone [see *Drug Interactions (7)*].

Drugs that Alter Gastric pH

Use of VYKAT XR with gastric pH adjusting-drugs is not expected to affect the pharmacokinetics of diazoxide. Based on population pharmacokinetic modeling, use of VYKAT XR with gastric pH adjusting drugs did not significantly affect relative bioavailability or apparent clearance of diazoxide.

Protein Binding Displacement

VYKAT XR may also displace bilirubin bound to serum protein, thus resulting in higher

blood levels of bilirubin.

In Vitro Studies

Enzyme systems: Diazoxide choline is an inhibitor of CYP1A2. It is not an inhibitor of CYP2B6, 2C19, 2C8, 2C9, 2D6 or 3A4. It does not induce CYP1A2, CYP2B6 or CYP3A4 at the therapeutic dose range.

Transporter systems: Diazoxide choline is a substrate for OAT1, OAT3, and BCRP. It is an inhibitor of OAT1/3. It is not an inhibitor of P-gp, BCRP, MATE1/2-K, OATP1B1/3, OCT1/2 at the therapeutic dose range.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies have not been performed with diazoxide choline.

Mutagenesis

Diazoxide choline was not mutagenic in the *in vitro* bacterial reverse mutation assay (Ames test) and in the mouse lymphoma assay. Diazoxide choline was not clastogenic in the *in vivo* rat micronucleus assay.

Impairment of Fertility

Diazoxide choline was orally administered to male and female rats at doses of 58, 116, and 232 mg/kg/day (1, 2, and 4 times the maximum recommended human dose (MRHD) on a mg/m² basis). Females were treated two weeks prior to mating and continuing through conception and implantation and males were treated for four weeks prior to mating continuing for 35 days after mating. No effects on male or female fertility parameters were observed. Decreases in the mean number of corpora lutea, implantation sites, and live embryos occurred at 4 times the MRHD on a mg/m² basis.

13.2 Animal Toxicology and/or Pharmacology

Cataracts were observed in dogs given repeated daily oral doses of diazoxide of approximately 40 mg/kg/day for one month. The lenticular changes resembled those which occur experimentally in animals with increased blood glucose levels.

14 CLINICAL STUDIES

The efficacy of VYKAT XR for the treatment of hyperphagia in adults and pediatric patients ages 4 years and older with PWS was established in a 16-week, double-blind, placebo-controlled, randomized withdrawal study period (Study 2-RWP; NCT03714373) that followed an open-label study period of VYKAT XR. During Study 2-RWP, 77 patients with hyperphagia and PWS were randomized in a 1:1 ratio to continue their current oral dosage using a weight-based dosage regimen of VYKAT XR or placebo [see *Dosage and Administration* (2.2)]. Prior to participating in Study 2-RWP, patients received double-blind and/or open-label VYKAT XR for a mean duration of 3.3 years (range 2.5 to 4.5 years; Study 1 and Study 2-OLE). Results from Study 2-RWP are presented below.

Demographic and baseline disease characteristics were similar for the VYKAT XR and placebo groups. The mean age was 14.9 years of age (range 7 to 29 years of age). Most of the participants were White (86%), 7% were Black or African American, and 8% were of multiple races. The majority of participants were non-Hispanic (91%) and female (56%).

The primary efficacy endpoint was the Change from Baseline in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Total Score at Week 16. The HQ-CT is a 9-item, observer-reported outcome measure that assesses a range of hyperphagic and food-related behaviors during the prior 2 weeks. An item score of 0 indicates an absence of behaviors, with a score of 4 indicating the most frequent or severe behaviors. The HQ-CT Total Score may range from 0 to 36, with higher scores indicating greater overall severity of hyperphagic and food-related behaviors.

At the end of the 16-week randomized withdrawal study period, there was statistically significant worsening of hyperphagia in the placebo group relative to the VYKAT XR group, as assessed by the HQ-CT Total Score (see Table 5).

Table 5: Study 2-RWP HQ-CT Total Score, Least Square Mean Change from Baseline to the End of the Randomized Withdrawal Period (Week 16) in Patients with Hyperphagia and PWS

Treatment Group	Number of Patients	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	LS Mean Difference* (95% CI)
VYKAT XR	38	9.0 (6.3)	2.6 (1.1)	-5.0 (-8.1, -1.8)
Placebo	39	8.1 (5.1)	7.6 (1.1)	

CI, confidence interval; HQ-CT, Hyperphagia Questionnaire for Clinical Trials; LS Mean, least squares mean; RWP, randomized withdrawal period; SD, standard deviation; SE, standard error

* VYKAT XR - placebo

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

VYKAT XR is supplied as follows:

Strength	Description	Package Configuration	NDC Number
25 mg diazoxide choline	White, capsule-shaped tablets, debossed with "S-25" on one side	30-count bottles	83860-025-01
75 mg diazoxide choline	White, round, standard convex tablets, debossed with "S-75" on one side	30-count bottles	83860-075-01
150 mg	White, oval-shaped		83860-

diazoxide choline	tablets, debossed with “S-150” on one side.	30-count bottles	05000- 150-01
----------------------	--	------------------	------------------

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature].

Keep in tightly closed container. Protect from humidity. Do not remove desiccant.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Administration Instructions

Advise patients to swallow tablets whole and not to split, crush, or chew VYKAT XR [see *Dosage and Administration (2.2)*].

Hyperglycemia

Advise the patient or caregiver that VYKAT XR can cause hyperglycemia, sometimes leading to diabetic ketoacidosis, and that the patient will have monitoring of blood glucose before and during VYKAT XR treatment. Advise patients or caregivers on the signs and symptoms of hyperglycemia (e.g., excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss) and ketoacidosis (e.g., nausea, vomiting, abdominal pain, generalized malaise and shortness of breath) and to contact their healthcare provider if these signs or symptoms occur [see *Warnings and Precautions (5.1)*].

Risk of Fluid Overload

Advise the patient or caregiver that VYKAT XR may cause edema, including severe adverse reactions associated with fluid overload. Advise patients or caregivers on the signs and symptoms of edema and to contact their healthcare provider if signs or symptoms of edema occur [see *Warnings and Precautions (5.2)*].

Manufactured for:

Soleno Therapeutics, Inc.

100 Marine Parkway, Suite 400

Redwood City, CA 94065

© 2025 Soleno Therapeutics, Inc. All rights reserved.

MEDICATION GUIDE **VYKAT™ XR (vye kat ex ar)** **(diazoxide choline)** **extended-release tablets, for oral use**

What is the most important information I should know about VYKAT XR?

VYKAT XR may cause serious side effects, including:

- **High blood sugar levels (hyperglycemia).** Hyperglycemia is common during treatment with VYKAT XR and can also be severe. Hyperglycemia can lead to a condition called diabetic ketoacidosis (increased ketones in the blood) in some people who take VYKAT XR. Diabetic ketoacidosis is a serious condition that needs to be

treated in a hospital and can be life-threatening.

Your healthcare provider will:

- check your blood sugar levels before you start VYKAT XR, at least 1 time every week for the first 2 weeks of treatment, then at least 1 time every 4 weeks and as needed during treatment.
- check your blood sugar more often during the first few weeks of treatment if you have an increased chance of getting hyperglycemia.
- check your HbA1c, which is another measurement of blood sugar control, before starting treatment, then 1 time every 3 months and as needed during treatment.

If you get hyperglycemia during treatment with VYKAT XR, your healthcare provider may:

- give you medicines to treat hyperglycemia or change your dose if you already take them
- change your dose, temporarily stop, or permanently stop VYKAT XR

Tell your healthcare provider if you get any of the following signs and symptoms:

- **hyperglycemia**
 - feel very thirsty
 - need to urinate more often than usual
 - have higher amounts of urine than usual
 - feel more hungry than usual
 - weight loss
- **diabetic ketoacidosis**
 - nausea
 - vomiting
 - stomach-area (abdominal) pain
 - feel weak or very tired
 - trouble breathing
- **Too much fluid in your body (fluid overload).** Swelling in the body (edema) from too much fluid is common during treatment with VYKAT XR and can also be severe. Your healthcare provider may decrease your dose or temporarily stop VYKAT XR if you get fluid overload. Tell your healthcare provider if you have trouble breathing or get any other signs or symptoms of fluid overload such as swelling of your legs, ankles, or feet, or unusual swelling anywhere in your body.

What is VYKAT XR?

VYKAT XR is a prescription medicine used to treat extreme hunger, constant thoughts about food, and constant urge to eat that cannot be satisfied with food (hyperphagia) in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). It is not known if VYKAT XR is safe and effective in children under 4 years of age.

Who should not take VYKAT XR?

Do not take VYKAT XR if you are allergic to diazoxide, any ingredients in VYKAT XR, or medicines called thiazides. See the end of this Medication Guide for a complete list of ingredients in VYKAT XR.

Before taking VYKAT XR, tell your healthcare provider about all of your medical conditions, including if you:

- have diabetes or prediabetes
- are sick
- plan to have surgery
- drink alcohol very often

- are dehydrated or have lost a lot of body fluid
- have heart problems or a history of swelling in your legs or other parts of your body
- have liver or kidney problems
- re pregnant, or plan to become pregnant. VYKAT XR may harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with VYKAT XR.
- are breastfeeding or plan to breastfeed. VYKAT XR passes into your breast milk, and it is not known if it can harm your baby. Tell your healthcare provider if you plan to breastfeed during treatment with VYKAT XR.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking VYKAT XR with certain other medicines may affect the way VYKAT XR or the other medicine works and may increase your risk of side effects.

Do not change your dose or stop any medicines you take or start any new medicines without talking to your healthcare provider first during treatment with VYKAT XR. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Especially tell your healthcare provider if you take:

- medicines to lower blood sugar
- growth hormones
- corticosteroids
- diuretics (water pills)
- phenytoin
- warfarin

How should I take VYKAT XR?

- Take VYKAT XR exactly as your healthcare provider tells you to take it. Your healthcare provider will decide how much VYKAT XR you will take and may slowly increase your dose when you first start taking VYKAT XR.
- Take VYKAT XR by mouth 1 time per day with or without food.
- Swallow VYKAT XR tablets whole. **Do not** split, crush, or chew the tablets.
- You should not miss a dose of VYKAT XR. If you miss a dose of VYKAT XR, take the missed dose as soon as you remember. Do not take 2 doses of VYKAT XR at the same time to make up for a missed dose. If you missed a dose of VYKAT XR and did not remember to take another dose, call your healthcare provider to discuss what you should do next.
- **The dose of VYKAT XR is not the same as diazoxide oral suspension. Do not change** between VYKAT XR and diazoxide oral suspension products.

If you take too much VYKAT XR, call your healthcare provider or Poison Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

What are the possible side effects of VYKAT XR?

- **See "What is the most important information I should know about VYKAT XR?"**

The most common side effects of VYKAT XR also include:

- increased hair growth all over the body
- rash

These are not all of the possible side effects of VYKAT XR. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store VYKAT XR?

- Store VYKAT XR at room temperature between 68°F to 77°F (20°C to 25°C).
- Close the bottle tightly after each dose.
- Keep VYKAT XR tablets dry (protect from humidity).
- The bottle contains a desiccant to help keep the tablets dry. Keep the desiccant in the VYKAT XR bottle.

Keep VYKAT XR and all medicines out of the reach of children.

General information about the safe and effective use of VYKAT XR.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VYKAT XR for a condition for which it was not prescribed. Do not give VYKAT XR to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VYKAT XR that is written for health professionals.

What are the ingredients in VYKAT XR?

Active ingredient: diazoxide choline

Inactive ingredients: carnauba wax, colloidal silicon dioxide, dibasic calcium phosphate dihydrate, hypromellose magnesium stearate, polyethylene oxide, silicified microcrystalline cellulose, talc, titanium dioxide, and triacetin.

Manufactured for: Soleno Therapeutics, Inc., 100 Marine Parkway, Suite 400, Redwood City, CA 94065

For more information, call 1-833-765-3661.

This Medication
Guide has been
approved by the
U.S. Food and
Drug
Administration.

Issued: 3/2025

Bottle Label - VYKAT XR - 25 mg
PRINCIPAL DISPLAY PANEL

NDC 83860-025-01

Vykat™ XR


(diazoxide choline)

Extended-Release Tablets

25 mg

Dispense the accompanying
Medication Guide to each patient

Rx only 30 tablets SOLENO® THERAPEUTICS



Bottle Label - VYKAT XR - 75 mg
PRINCIPAL DISPLAY PANEL

NDC 83860-**075**-01

VykatTM XR


(diazoxide choline)

Extended-Release Tablets

75 mg

**Dispense the accompanying
Medication Guide to each patient**

Rx only 30 tablets SOLENO[®] THERAPEUTICS



Bottle Label - VYKAT XR - 150 mg
PRINCIPAL DISPLAY PANEL

NDC 83860-**150**-01

VykatTM XR

(diazoxide choline)

Extended-Release Tablets

150 mg

**Dispense the accompanying
Medication Guide to each patient**

Rx only 30 tablets SOLENO[®] THERAPEUTICS



VYKAT XR

diazoxide choline tablet, film coated

Product Information				
Product Type		HUMAN PRESCRIPTION DRUG	Item Code (Source)	
Route of Administration		oral		
Active Ingredient/Active Moiety				
Ingredient Name			Basis of Strength	Strength
diazoxide choline (UNII: 2U8NRZ 7P8L) (diazoxide - UNII:O5CB12L4FN)			diazoxide choline	25 mg
Product Characteristics				
Color	white	Score	no score	
Shape	capsule	Size	13mm	
Flavor		Imprint Code	S25	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:83860-025-01	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/26/2025	
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA		NDA216665	03/26/2025	

VYKAT XR

diazoxide choline tablet, film coated

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:83860-075
Route of Administration	oral		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
diazoxide choline (UNII: 2U8NRZ 7P8L) (diazoxide - UNII:O5CB12L4FN)	diazoxide choline	75 mg

Product Characteristics			
Color	white	Score	no score
Shape	round	Size	9mm
Flavor		Imprint Code	S75
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:83860-075-01	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/26/2025	

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA216665	03/26/2025	

VYKAT XR

diazoxide choline tablet, film coated

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:83860-150
Route of Administration	oral		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
diazoxide choline (UNII: 2U8NRZ 7P8L) (diazoxide - UNII:O5CB12L4FN)	diazoxide choline	150 mg

Product Characteristics			
Color	white	Score	no score

Shape		oval	Size	15mm
Flavor			Imprint Code	S150
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:83860-150-01	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/26/2025	
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA		NDA216665	03/26/2025	

Labeler - Soleno Therapeutics, Inc. (030593896)

Registrant - Soleno Therapeutics, Inc. (030593896)